JPMorgan Chase & Co. Reaffirms Overweight Rating for G1 Therapeutics (GTHX)

JPMorgan Chase & Co. reissued their overweight rating on shares of G1 Therapeutics (NASDAQ:GTHX) in a research note published on Tuesday. They currently have a $39.00 price objective on the stock, up from their prior price objective of $33.00.

GTHX has been the subject of a number of other reports. BidaskClub upgraded shares of G1 Therapeutics from a sell rating to a hold rating in a research note on Wednesday, January 3rd. Cowen reiterated a buy rating on shares of G1 Therapeutics in a research note on Monday, March 5th. BTIG Research reiterated a buy rating and issued a $38.00 price objective on shares of G1 Therapeutics in a research note on Thursday, February 22nd. Finally, Zacks Investment Research upgraded shares of G1 Therapeutics from a sell rating to a hold rating in a research note on Monday, February 26th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $36.60.

How to Become a New Pot Stock Millionaire

G1 Therapeutics (NASDAQ GTHX) opened at $34.23 on Tuesday. G1 Therapeutics has a one year low of $12.04 and a one year high of $35.24.

G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings data on Wednesday, February 21st. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.02). research analysts forecast that G1 Therapeutics will post -2.47 earnings per share for the current fiscal year.

In other news, insider Rajesh Malik sold 3,776 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $20.00, for a total transaction of $75,520.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mark A. Velleca sold 7,500 shares of the business’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of $20.01, for a total transaction of $150,075.00. The disclosure for this sale can be found here. Insiders have sold a total of 217,302 shares of company stock valued at $4,314,417 over the last 90 days.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. American International Group Inc. purchased a new position in shares of G1 Therapeutics during the 3rd quarter valued at $130,000. California State Teachers Retirement System purchased a new position in shares of G1 Therapeutics during the 3rd quarter valued at $319,000. Teachers Advisors LLC grew its position in shares of G1 Therapeutics by 44.6% during the 4th quarter. Teachers Advisors LLC now owns 13,818 shares of the company’s stock valued at $274,000 after purchasing an additional 4,260 shares in the last quarter. Swiss National Bank purchased a new position in shares of G1 Therapeutics during the 4th quarter valued at $286,000. Finally, Schwab Charles Investment Management Inc. purchased a new position in shares of G1 Therapeutics during the 3rd quarter valued at $364,000. Hedge funds and other institutional investors own 47.54% of the company’s stock.

TRADEMARK VIOLATION WARNING: “JPMorgan Chase & Co. Reaffirms Overweight Rating for G1 Therapeutics (GTHX)” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at https://sportsperspectives.com/2018/03/10/jpmorgan-chase-co-reaffirms-overweight-rating-for-g1-therapeutics-gthx.html.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Analyst Recommendations for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply